Hamol Biosolutions offers services for the design, development and manufacture of peptide based biologic therapeutics mainly in the areas of cardiovascular medicine and infection-related research. The company's therapeutics pipeline has two candidates, HB-ATV-8, a needle free mucosal therapeutic vaccine for atherosclerosis entering phase I, and HB-SCT-16, a peptide to treat diseases caused by Gram-negative bacteria in the preclinical stage. HB-CETP, their diagnostic kit for measuring the levels of Cholesterol-Ester Transfer Protein (CETP) in human plasma is close to validation and is expected to reach the market. The company claims to have close ties with academic institutions in the US and Mexico.